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 Abstract 
 Background: Previous data have pointed to the fact that vascular function is significantly im-
paired in patients with end-stage renal disease (ESRD). We aimed to better characterise vaso-
dilation and exercise capacity in both ESRD and chronic heart failure (CHF) patients.  Methods: 
A total of 30 ESRD patients (23 male; mean age 45.7 ± 9.9 years) were included in a prospec-
tive proof-of-concept study at a tertiary care academic centre. The patients underwent fore-
arm venous plethysmography with post-ischaemic peak blood flow (PF) and flow-dependent 
flow (FDF) testing as well as cardiopulmonary exercise testing during the morning of the day 
following the last haemodialysis. After matching for age, gender, and body mass index, the 
data were compared to 30 patients with CHF and 20 age-matched healthy controls.  Results: 
PF in ESRD patients was reduced when compared to that in CHF patients (12.5 ± 4.2 vs. 15.6 
± 6.9 ml/100 ml/min; p = 0.048) and healthy controls (26.4 ± 9.3 ml/100 ml/min; p < 0.001). 
When compared to controls, FDF was significantly reduced in ESRD patients (7.6 ± 3.1 vs. 6.0 
± 2.5 ml/100 ml/min; p = 0.03), but not in CHF patients, whereas resting blood flow did not 
differ between the ESRD, CHF, and healthy control groups. In contrast to indices of vasodila-
tive capacity, maximum exercise capacity (peakVO 2 ) was higher in ESRD when compared to 
CHF patients (23.8 ± 7.3 vs. 18.8 ± 5.2 ml/min/kg), but significantly impaired when compared 
to controls (32.8 ± 6.7 ml/min/kg; p < 0.001).  Conclusion: In this proof-of-concept study, ex-
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ercise capacity was relatively preserved, while vasodilative capacity was substantially impaired 
in ESRD patients. Additional studies are warranted to examine the underlying mechanisms 
and potential clinical implications of our findings.  © 2016 S. Karger AG, Basel 
 Introduction 
 Renal failure requiring initiation of renal replacement therapy affects all organ systems 
and is associated with high mortality rates in both the chronic  [1–3] and the acute clinical 
setting  [4–6] . The excessive morbidity and mortality of patients with end-stage renal disease 
(ESRD) seems mostly due to cardiovascular complications  [1–3, 7–9] . Therefore, it seems 
perfectly acceptable that ESRD both on and off renal replacement therapy may be regarded a 
vasculopathic state in itself  [10] . Several cofactors (e.g. diabetes, age, and time on dialysis) 
may be regarded key determinants of the overall (cardio-)vascular risk  [1, 2, 9, 11] . In addition, 
cofactors such as malnutrition/cachexia  [2, 12, 13] and induction of multiple inflammatory 
pathways  [14–18] contribute to increased vasculopathy and, finally, adverse outcomes in 
affected patients.
 Macroangiopathy represents the (often clinically visible) endpoint of vasculopathy, 
whereas the initial stage includes more subtle dysfunctions of the vascular endothelium 
which may require more sophisticated imaging and/or functional testing  [1, 10, 19–21] . 
Theoretically, however, early detection of endothelial dysfunction may help to improve 
patients’ prognosis via better risk stratification of the respective cohorts and/or timely 
induction of targeted therapy. However, it should be noted that renal failure and cardiac 
failure interact on endothelium-derived vasodilative capacity. Previous data have demon-
strated that in patients with chronic heart failure (CHF), peripheral endothelial dysfunction 
occurs at early clinical stages but predicts long-term adverse outcome  [20] . On CKD patients, 
however, the data are scarcer. Following correction for traditional cardiovascular risk factors, 
the data indicate that especially patients close to initiation of dialysis or ESRD patients on 
dialysis in particular seem to have significant endothelial dysfunction  [1, 10, 19, 21, 22] . 
Nevertheless, a diminished vasodilative capacity may also be observed at earlier stages, i.e. 
at Kidney Disease Outcomes Quality Initiative (KDOQI) stages 2 and 3.
 In an effort to better characterise vasodilative capacity and exercise capacity in ESRD, we 
investigated forearm post-ischaemic (peak) blood flow (PF; in an effort to define the maximum 
possible vasodilation), flow-dependent flow (FDF) (both assessed by non-invasive measures), 
and peak oxygen uptake per body weight (peakVO 2 ). For assessment of endothelial function, 
forearm venous plethysmography was chosen, which may be regarded as an established non-
invasive method with a long-standing record. Transient ischaemia provokes the release of 
nitric oxide (NO), resulting in vasodilation which can be quantified as an index of vasomotor 
function and measured by means of ultrasound or strain gauge. It allows a differentiation 
between maximum possible flow (i.e. PF) resulting from ischaemia and NO-mediated, i.e. 
flow-dependent, flow (FDF) resulting from endothelium-derived NO release derived from 
shear stress. However, the assessment of endothelial function requires comparable and 
comprehensive rating of the cardiovascular system, which can be characterised by exercise 
capacity with maximum oxygen uptake (as in peakVO 2 ) as a ‘gold standard’ for CHF and also 
as a strong predictor of survival in ESRD  [23–26] .
 In the current proof-of-concept investigation, we set out to investigate whether endo-
thelial function in ESRD is proportional to exercise capacity, and we compared this relation to 
patients with CHF and healthy control subjects. Moreover, we were interested in whether age 
and time since initiation of chronic dialysis would be factors influencing endothelial function.
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 Subjects and Methods 
 Study Cohorts and Study Visits 
 A total of 30 ESRD patients (23 male; mean age 45.7 ± 9.9 years, range 26–64; 87% on haemodialysis) 
were included in a single-centre prospective observational proof-of-concept study at the outpatient clinic of 
a tertiary care academic centre (Kidney Transplantation Centre, Charité – Universitätsmedizin Berlin, Berlin, 
Germany). All patients were awaiting kidney transplantation, either on the Eurotransplant waiting list (n = 
15) or scheduled for kidney transplantation from living donors (i.e. from relatives; n = 15). The median time 
since initiation of chronic haemodialysis was 18.0 months (range 1–240). With regard to examination of the 
participating subjects, special attention was paid to the interval between the last haemodialysis and the 
respective study visit, due to the fact that most of the parameters could theoretically be influenced by fluid 
overflow, imbalance of electrolytes, or accumulation of metabolites. Thus, an interval of approximately 
19–22 h (the typical time interval between the end of morning dialysis and the study visit the following 
morning) was chosen. In an effort to minimise any potential bias introduced by fluid overload, a difference 
from post-dialysis weight (‘dry weight’) of less than 1% (or 1 kg) was allowed for. Patients on peritoneal 
dialysis were excluded from the analysis. All patients had been fasting before venous plethysmography and 
drawing of blood samples, whereas the exercise test was performed after a light breakfast and a short resting 
period. Medication was taken with the breakfast but not before plethysmography.
 In all, 30 CHF patients were recruited from the CHF outpatient clinic of the Charité – Universitätsmedizin 
Berlin, and they were matched for age, gender, and body mass index. The aetiologies of heart failure were 
dilative cardiomyopathy (n = 16) and coronary heart disease (n = 14; 47%). Twenty healthy volunteers of 
the same age served as controls.
 The study was approved by the local ethics committee (Ethikkommission Charité, Berlin, No. 16003) 
and informed written consent was obtained from all patients. The study was performed in accordance with 
the ethical guidelines established in the Declaration of Helsinki.
 Assessment of Vascular Capacity and Peripheral Blood Flow 
 In general, plethysmography may allow checking for volume changes in the area of interest, since such 
changes were shown to be directly related to the amount of blood flow. In an effort to assess peripheral blood 
flow and vascular capacity, we applied venous occlusion plethysmography using a commercial EC6 plethys-
mography device (Hokanson Inc., Bellevue, Wash., USA). As is proposed for performing these measurements, 
the subjects were requested to rest in the supine position for at least 15 min, and forearm blood flow was 
determined using a mercury-in-silastic strain gauge (Hokanson Inc.). A circumferential cuff around the right 
upper arm was connected to a rapid inflation pump with an air source and solenoid valves, used to inflate 
and deflate the occlusion cuff rapidly to the required pressure of 40 mm Hg. After the resting period, the blood 
flow was measured on the arm without the dialysis fistula and calculated as resting flow. To measure the PF, 
the cuff was inflated to suprasystolic pressures (i.e. 30 mm Hg above the systolic blood pressure) for 3 min. 
Blood flow was measured after release of the cuff in 10-second intervals for at least 2 min. The highest flow 
results were considered to represent PF.
 For assessment of FDF, which may serve as an estimate of endothelium-dependent vasodilator capacity, 
a second sphygmomanometer cuff was placed distal to the strain gauge on the forearm and inflated to supra-
systolic levels for 2 min. After sudden deflation of this cuff, the increase in shear stress due to the increased 
flow through the brachial artery causes endothelium-derived NO release. Following this re-induction of 
increased brachial artery blood flow, consecutive blood flow was then measured every 10 s for a total period 
of 90 s. Absolute values derived from the plethysmographic measurements are given as millilitres per 100 
ml tissue per minute (ml/100 ml/min).
 Exercise Testing 
 A symptom-limited cardiopulmonary exercise test was performed on a treadmill according to the 
modified Naughton protocol. Expired gas was sampled through a ‘Rudolph mask’ conveyed to a spirometer 
and to oxygen/carbon dioxide detectors (Medgraphics, Vadnais Heights, Minn., USA). VO 2 and VCO 2 , the end-
tidal expiratory gas concentrations p ET O 2 and p ET CO 2 , and ventilation per minute VE were measured breath 
by breath, and the average of 5 out of 7 breaths was calculated automatically. All patients were monitored with 
a continuous 12-lead electrocardiogram (CardioPerfect; Welch Allyn, New York, N.Y., USA), and non-invasive 
blood pressure measurement was conducted at rest, at every stage of the exercise, and during recovery. Data 
at rest and FEV 1 (forced expiratory volume in the first second) were determined after 3 min of quiet standing 
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and breathing via the mask. Exercise time was recorded and symptoms at peak exercise were documented. 
All patients exercised until limited by symptoms. For peakVO 2 , peakVCO 2 , and peakVE, the highest readings 
of each parameter in the final 30 s of exercise were used. Respiratory exchange ratio was used as a marker of 
exhaustion and calculated from peakVCO 2 and peakVO 2 (i.e. peakVCO 2 /peakVO 2 ). Ventilatory efficiency 
during exercise testing was measured by plotting VE against VCO 2 , values due to hyperventilation (acidosis) 
in the last minutes of exercise were excluded, and the slope of the revealed linear relationship (VE/VCO 2 
slope) was calculated by linear regression and accepted if the correlation coefficient r was >0.95.
 Blood Samples 
 Peripheral venous blood samples for the measurement of creatinine, electrolytes, and haemoglobin 
were taken at the beginning of the visit after 30 min of rest in a fasting condition and analysed immediately 
in a certified laboratory (Charité – Universitätsmedizin).
 Statistical Analysis 
 All analyses were performed using SPSS 18.0 (IBM, Chicago, Ill., USA). Data are given as means ± SD for 
parametric variables, and as medians with interquartile ranges for the non-parametric variables ‘time since 
(initiation of) first dialysis’ and New York Heart Association (NYHA) stage. Differences between the three 
groups (ESRD, CHF, and controls) were calculated using two-tailed Student’s unpaired t test and the Mann-
Whitney test, as appropriate. The distribution of gender (i.e. proportion of females) and comorbidities 
(including diabetes, hypertension, and medication) was compared by χ 2 testing. Correlations between 
different quantitative parameters were assessed by linear or by Spearman’s correlation, as appropriate. p < 
0.05 was considered significant.
 Results 
 Patient Characteristics 
 The characteristics of the study population, including (co-)medications, are outlined in 
 table 1 . The prevalence of arterial hypertension in about 90% of the subjects marks a relevant 
comorbidity but seems rather unavoidable in ESRD populations. The majority of the patients 
trended for normalization of blood pressure under therapy, with mean pressures at rest of 
126.2 ± 19.9/75.0 ± 10.5 mm Hg (systolic/diastolic). At exercise, the respective mean systolic 
and diastolic blood pressures were 161.5 ± 28.8 and 79.1 ± 8.9 mm Hg. Diverse aetiologies of 
renal failure were noted in the study group, which may be due to the fact that patients from 
a tertiary care academic referral centre were included. Exercise insufficiency was not prev-
alent in the ESRD cohort, and thus, by definition, the majority of the patients were clinically 
in NYHA stage I, subjectively corresponding to only slightly impaired everyday capacity and 
an average peakVO 2 of about 22 ml/min/kg. An additional analysis was performed to char-
acterise residual renal function and the haemodialysis dose applied, because both factors may 
influence endothelial function and exercise capacity. Although measured on the off-dialysis 
day, the mean creatinine levels were relatively high (i.e. 7.4 ± 2.6 mg/dl). However, due to 
insufficient data provided by ambulatory care practitioners, a formal calculation of dialysis 
dose (i.e. by Kt/V) was not possible. Therefore, we used creatinine levels as a rough approxi-
mation to short-time dialysis quality.
 The comparator cohorts with CHF patients and healthy subjects were matched for age 
and gender, but they differed expectedly for concomitant medication and blood pressure 
( table 2 ). All study participants underwent exercise testing until limited by symptoms, and 
exhaustion was defined as a respiratory ratio (VCO 2 /VO 2 ) of 1.1 ± 0.1.
 Vasodilative Capacity 
 No difference in blood flow at rest between ESRD patients (4.8 ± 2.5 ml/100 ml/min), 
CHF patients (4.7 ± 3.6 ml/100 ml/min), and healthy subjects (5.0 ± 2.3 ml/100 ml/min) (all 
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p > 0.6) was noted. Maximum vasodilation (peak flow) after ischaemic provocation in ESRD 
patients (12.5 ± 4.2 ml/100 ml/min) was lower than in CHF patients (15.6 ± 6.9 ml/100 ml/
min; p = 0.048 vs. ESRD) and substantially lower than in healthy controls (26.4 ± 9.3 ml/100 
ml/min; p < 0.001 vs. ESRD). FDF was diminished in both ESRD patients (6.0 ± 2.5 ml/100 
ml/min) and CHF patients (7.4 ± 4.6 ml/100 ml/min; p = 0.14) when compared to healthy 
subjects (7.6 ± 3.1 ml/100 ml/min; p = 0.03 vs. ESRD). Between-group comparisons are given 
in  figure 1 .
 Several parameters were assessed as cofactors for flow at rest, PF, and FDF. A correlation 
with age was not found in ESRD patients. In this group, the correlation coefficient r between 
 Table 1.  Baseline characteristics of the ESRD patients (n = 30)
Demographics
Age, years 45.7 ± 9.9
Male 23 (76.7)
Time since initiation of haemodialysis, months 18.0 [12.5]
Body mass index 24.5 ± 4.0
Aetiology of renal failure
Glomerulonephritis 3 (10)
Diabetic nephropathy 3 (10)
Polycystic kidney disease 3 (10)
Intrarenal cause/toxicity 2 (6.7)
Post-pyelonephritis 2 (6.7)
Othersa 6 (20)
Unknown 11 (40)
Concomitant diseases
Arterial hypertension 26 (86.7)
Coronary heart disease 19 (25.0)
Diabetes mellitus 18 (23.7)
Chronic viral infection (hepatitis B/C, HIV) 6 (7.9)
Clinical data
NYHA stage 0.8 [1 – 3]
Blood pressure at rest, mm Hg 124.5 ± 17.8
Heart rate at rest, beats/min 81.7 ± 15.7
Medication
Beta-blocker 10 (33.3)
Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker 11 (36.7)
Diuretics 25 (83.3)
Ca antagonist 5 (36.8)
Number of antihypertensive drugs 2.0 [0 – 7]
Acetylsalicylate 1 (3.3)
Statins 6 (20)
Laboratory values
Serum creatinine,  mg/dl 7.4 ± 2.6
Serum urea, mg/dl 107.6 ± 45.5
Serum uric acid, mg/dl 5.4 ± 1.8
Haemoglobin, mg/dl 12.6 ± 1.7
HbA1c, % 5.8 ± 1.1
Total cholesterol, mg/dl 182 ± 48
Values are presented as n (%), mean ± SD, or median [interquartile range]. a Indicates the following 
diagnoses: Alport syndrome, IgA nephropathy, Fabry disease, granulomatosis with polyangiitis (Wegener’s), 
or renal hypoplasia/nephrosclerosis.
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age and flow at rest was –0.3, between age and PF it was 0.11, and between age and FDF it 
was –0.19 (all p > 0.1). Regarding gender as a cofactor, there was a non-significant tendency 
towards lower flow in female patients. The flow at rest in males versus females was 4.9 ± 2.6 
versus 4.5 ± 2.1 ml/100 ml/min, PF was 13.2 ± 4.2 versus 10.4 ± 3.7 ml/100 ml/min, and FDF 
was 6.2 ± 2.3 versus 5.5 ± 3.2 ml/100 ml/min (p > 0.1 for all comparisons). Additionally, 
neither time since initiation of (first) dialysis nor current creatinine level nor peakVO 2 was 
found to correlate with FR, PF, or FDF. In addition, no respective correlation was found in 
either the CHF or the healthy control group. In addition, no gender-dependent differences 
regarding flow variables were noted in the CHF and healthy control groups (p > 0.08).
 Exercise Capacity and Ventilatory Efficiency 
 Maximum exercise capacity (i.e. peakVO 2 ) was impaired in ESRD patients (23.8 ± 7.3 ml/
min/kg), corresponding to an anaerobic threshold at 13.6 ± 3.8 ml/min/kg and a ventilatory 
 Table 2. Between-group comparison of baseline demographics and disease severity
ESRD 
patients
(n = 30)
CHF 
patients
(n = 30)
Healthy 
controls
(n = 20)
Between-group 
p value
Age, years 45.7 ± 9.9 48.9 ± 7.6 49.3 ± 7.4 n.s.
Female 7 (23.3) 6 (20) 5 (20) n.s.a
Body mass index 24.5 ± 4.0 27.2 ± 4.4 25.7 ± 4.4 n.s.
Coronary heart disease 4 (13.3) 14 (47) – 0.001a
Diabetes mellitus 6 (20) 8 (26.7) – n.s.a
NYHA stage 0.9 [1 – 3] 3.0 [1 – 4] – <0.001b
Systolic blood pressure at rest, mm Hg 126.2 ± 19.9 114.2 ± 16.3 124.9 ± 11.8 <0.01
Diastolic blood pressure at rest, mm Hg 75.7 ± 11.7 71.8 ± 17.5 73.7 ± 15.0 n.s.
Serum creatinine, mg/dl 7.4 ± 2.6 1.3 ± 0.9 – <0.001
Values are presented as n (%), mean ± SD, or median [interquartile range]. n.s. = Not significant. a χ2 test. b Mann-
Whitney U test.
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 Fig. 1. Blood flow at rest ( a ), post-ischaemic flow ( b ), and FDF ( c ) in patients with ESRD and CHF and in 
healthy controls (means and percentiles are given).  * p < 0.05,  * * p < 0.001. 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
 B
er
n 
   
   
   
   
   
   
   
   
   
   
   
   
  
13
0.
92
.1
75
.1
66
 - 
1/
9/
20
17
 1
:2
1:
40
 P
M
56Cardiorenal Med 2017;7:50–59
 DOI: 10.1159/000449174 
 Habedank et al.: Vasodilation and Exercise Capacity in Patients with End-Stage Renal 
Disease: A Prospective Proof-of-Concept Study 
www.karger.com/crm
© 2016 S. Karger AG, Basel
efficiency (VE/VCO 2 slope) of 29.3 ± 5.6. Inverse correlations of age with peakVO 2 (r = –0.42; 
p < 0.001) and VE/VCO 2 slope were noted (r = 0.38; p < 0.001). peakVO 2 correlated inversely 
with time since initiation of dialysis (ρ = –0.26; p = 0.027) but not with serum creatinine levels 
(r = 0.24; p = 0.08). Similarly to peakVO 2 , ventilatory efficiency (VE/VCO 2 slope) correlated 
with age (r = 0.38; p = 0.001) and haemoglobin concentrations (r = –0.32; p = 0.013).
 The peakVO 2 of the CHF patients was significantly lower (18.8 ± 5.2 ml/min/kg) when 
compared to ESRD patients (p = 0.003) and healthy subjects (32.8 ± 6.7 ml/min/kg; p < 
0.001). Correspondingly, the VE/VCO 2 slope was highest in CHF patients (34.1 ± 7.2), with 
healthy controls at 28.7 ± 5.2 (p = 0.007). For comparison of peakVO 2 levels, please see 
 figure 2 .
 Discussion 
 Here we demonstrated that in ESRD, endothelium-derived vasodilative capacity is 
reduced to an extent typically observed in NYHA stage III heart failure patients despite better 
exercise capacity. ESRD patients were found to have a significantly lower FDF than age-
matched healthy controls, and the PF was impaired by 48% (again corresponding to levels of 
patients with advanced heart failure). However, we noted no correlations of indices of endo-
thelial function with cofactors such as age, peakVO 2 , or time since initiation of dialysis.
 The ‘gold standard’ (peakVO 2 ) of exercise testing was evaluated more than 25 years ago 
in ESRD patients  [26] and was shown to predict survival in this population. In the current 
analysis, we observed rather high peakVO 2 levels (about 24 ml/min/kg) in our population 
that may be regarded as being in the higher range when compared to other investigations. 
Thus, the physical condition of the cohort investigated here may be rather preserved, and 
impaired FDF and PF may indicate that vascular function in older or more comorbid patients 
may even be worse. Nevertheless, a methodological comparison of FDF measurements in 
ESRD patients may be challenging due to the fact that the vast majority of studies used ultra-
sound to measure flow-dependent vasodilatation instead of venous occlusion plethysmog-
raphy. However, the latter may be easier to perform, and normal levels from healthy volun-
teers are available  [27] . The normal values provided by Boutcher and Boutcher  [28] are 
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higher (max. vasodilative capacity 35 ± 10 ml/100 ml/min) but derive from considerably 
younger male subjects. In addition, the normal value provided by Meredith et al.  [29] for peak 
flow in younger healthy volunteers was 26.5 ± 2.1 ml/100 ml/min, but this group used a 
different methodological approach. In summary, studies on endothelial function in ESRD 
demonstrate impaired FDF in relation to normal subjects. However, as outlined above, these 
data are challenging to compare due to significant methodological differences.
 A further limitation of all studies may consist in the fact that the basic assumption is that 
FDF is simply NO dependent. However, endothelial function seems much more complex, since 
e.g. adenosine, cyclooxygenase metabolites, and potassium channels may contribute to 
vascular relaxation  [30] . Nevertheless, as these are at least partly reflected by peak flow 
measurements, we are convinced that the combination of both impaired FDF and impaired 
PF indicates severe endothelial dysfunction in ESRD patients. London et al.  [31] aimed to 
avoid any such limitations and proposed a novel parameter, i.e. ‘flow debt repayment’, derived 
from strain gauge plethysmography, which may characterise endothelium-derived vasodi-
lation. This parameter was shown to be predictive of all-cause mortality of ESRD patients. 
However, it should be noted that this parameter requires sophisticated assessment, is not 
broadly accepted, and lacks reference ranges.
 Our study has further limitations that require discussion. First, it seems important to 
note that only a small sample from a single centre was investigated. Thus, a key limitation 
might primarily be driven by the study design, and inherent limitations including the proof-
of-concept character of the study must be borne in mind when interpreting our data. Moreover, 
we are currently unable to examine the underlying mechanisms and clinical implications of 
the effects observed. Additional studies are therefore warranted. Second, as mentioned 
before, due to the complexity of the biological function of the endothelium, endothelial 
function may not simply be reduced to being NO dependent. Consecutively, FDF must be 
interpreted as only partially reflecting the complexity of the endothelial response. Never-
theless, one of the strengths of this study might be that we aimed to employ rather elaborate 
methods for PF and FDF assessment.
 In the present study we did not find that time since initiation of dialysis (i.e. total time on 
dialysis) correlates with indices of endothelial function, and this may be due to the fact that 
the onset of renal failure is not simply linked to starting of renal replacement therapy. Never-
theless, endothelial dysfunction was shown to be present in early stages of CKD  [1, 2, 10, 19, 
21, 32] , and data from renal transplant recipients demonstrate that this condition seems at 
least partly reversible  [33] .
 In summary, in our proof-of-concept study involving a limited number of study patients, 
the endothelium-derived vasodilative capacity of ESRD patients was found to be significantly 
reduced by about 20% (FDF) and 48% (PF) when compared to normal subjects, which corre-
sponds to levels observed in patients with advanced CHF (NYHA stage III). Impaired endo-
thelial function in ESRD stands in contrast to rather preserved exercise capacities. We spec-
ulate from our data that the fairly preserved exercise capacity in the cohort under investi-
gation may point to the fact that endothelial dysfunction precedes cardiopulmonary limitations 
by a substantial period in time. Additional studies thus seem warranted to examine the under-
lying mechanisms and potential clinical implications of our findings.
 Statement of Ethics 
 This study was approved by the local ethics committee (Ethikkommission Charité, Berlin, Germany, No. 
16003), and written informed consent was obtained from all patients. The study was performed in accor-
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